TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02945358

Intervention type: PROCEDURE
Intervention: adult cardiac surgery with cardiopulmonary pump
Description: Open-heart surgery both coronary artery bypass graft (CABG) and valve surgery
Study: NCT02016716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab 90 mg/mL
Description: Administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL crystal zenith resin prefilled syringe (PFS).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo 90 mg/mL
Description: Placebo administered as 2 SC injections with the 1.17 mL crystal zenith resin PFS.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab 70 mg/mL
Description: Administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL glass PFS.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 70 mg/mL
Description: Placebo administered as 3 SC injections with the 1.0 mL glass PFS.
Study: NCT02248649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured physical activity
Description: Walking instruction and encouragement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Provision of general information about a variety of health topics
Study: NCT04734483

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: spirometry
Description: spirometry

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: spirometry
Description: spirometry

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: MRI and CT
Description: MRI and CT

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: MRI and CT
Description: MRI and CT

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscopy
Description: laryngoscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laryngoscopy
Description: laryngoscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electromyography
Description: electromyography

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: electromyography
Description: electromyography
Study: NCT01505036

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMARTCARE service
Description: U-Healthcare service
Study: NCT05026840

Intervention type: PROCEDURE
Intervention: GDM screening criteria
Description: difference in risk factors and clinical outcomes between groups

Intervention type: PROCEDURE
Intervention: GDM screening criteria
Description: difference in risk factors and clinical outcomes between groups
Study: NCT01832389

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PiCCO
Study: NCT02504398

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fast injection speed by immunizer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Slow injection speed by immunizer
Study: NCT03954834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered SC
Study: NCT01188278

Intervention type: DRUG
Intervention: Imatinib
Description: Drug being observed but not provided
Study: NCT01631071

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virosomal influenza vaccine
Description: Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL virosomal influenza vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Virosomal influenza vaccine
Description: Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL virosomal influenza vaccine
Study: NCT02601638

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Demographics and Health History Questionnaire

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pre-Class Laryngectomy Survey
Study: NCT03529825

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Rifaximin will be administered twice a day orally or by nasogastric tube, at a dose of 15 mg/kg divided BID with a maximum dose of 1,650 mg, day -7 to day +28 or discharge (maximum duration 36 days).
Study: NCT04322110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PronoKal Method
Description: Multidisciplinary program of weight loss based on diet (initially ketogenic diet), physical activity and emotional support

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low calorie diet
Description: Balanced hypocaloric diet (caloric intake 10% below basal metabolic rate) accompanied by physical exercise.
Study: NCT02076490

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical/Occupational therapy
Description: At least 10 individual sessions over the clinical intervention period of 4 weeks followed by a 6 weeks self-management phase.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical/Occupational therapy
Description: At least 10 individual sessions over the clinical intervention period of 4 weeks followed by a 6 weeks self-management phase.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical/Occupational therapy
Description: At least 10 individual sessions over the clinical intervention period of 4 weeks followed by a 6 weeks self-management phase.
Study: NCT03398070

Intervention type: OTHER
Intervention: Standard of Care
Description: The standard of care interventions for Functional Neurological Disorders (FND) include:~1. delivery of a rule-in diagnosis~2. providing educational materials~3. referring to physical therapy (PT) and/or occupational therapy (OT) as clinically indicated~4. referring to FND-related cognitive behavioral therapy (CBT)~5. psychotropic medication management based on standard psychiatric care
Study: NCT03893565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2831781 - Double Blind Phase
Description: GSK2831781 will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (commercial saline solution) will be administered intravenously in the double blind induction phase and subcutaneously in the double blind ETP (both according to randomization).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2831781 - Open Label phase
Description: GSK2831781 will be administered intravenously in the open label induction phase and subcutaneously in the open label ETP.
Study: NCT04918485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: preoperative psychological intervention
Description: including closing the relationship between nurse and patient , knowledge education,
Study: NCT00813800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline (Chantix®, Pfizer) is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.
Study: NCT04256512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02840929

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Second-look OGD
Description: Second-look OGD within 16 to 24 hours after primary OGD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Study: NCT03566992

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Gastric
Description: Placement of a nasoenteric tube

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric
Description: Placement of a nasoenteric tube
Study: NCT02835235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NNC9204-0530
Description: Administered daily subcutaneously (s.c., under the skin)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered daily subcutaneously (s.c., under the skin)
Study: NCT00471315

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Duloxetine
Description: A preliminary, open-label single center study of duloxetine in patients with SOD
Study: NCT01250899

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 50,000 IU vitamin D3 twice weekly for 5 weeks, followed by 2000 IU daily maintenance supplementation to complete 12 weeks. At the end of the 12-week period, 25(OH)D levels will be checked. If the subject is still deficient, he/she may undergo a second period of supplementation (at the discretion of their provider) to complete a total of 24 weeks. After 24 weeks, we anticipate all subjects will be kept on daily maintenance supplementation by their primary physicians.
Study: NCT03024229

Intervention type: DEVICE
Group type: OTHER
Intervention: LifePort® perfusion machine
Description: Renal perfusion on LifePort® machine
Study: NCT02620124

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural cycle: Triptorelin acetate 0.1 mg
Description: A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in additon to standard micronized progesterone 400 mg vaginally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natural cycle: Triptorelin acetate 0.1 mg
Description: A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in additon to standard micronized progesterone 400 mg vaginally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormone replacement cycle and triptorelin acetate 0.1 mg
Description: A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in addition to standard Estradiol and progesterone support
Study: NCT04162262

Intervention type: OTHER
Group type: OTHER
Intervention: Instrumental-assisted soft tissue mobilization (IASTM)
Description: Instrumental-assisted soft tissue mobilization (IASTM) will consist of treatment focused on the plantar surfaces of foot, posterior heel, and lower leg. The IASTM will be implemented using Graston Technique Instruments by clinicians trained and certified in the technique. Each 10-minute treatment will consist of two phases: 1) six-minute static phase, which includes tissue status screening and soft tissue mobilization, and 2) four-minute dynamic tissue mobilization phase. The treatment will focus on the web spaces of each toe plantarly, the metatarsal heads, the spaces between metatarsals, the medial and lateral plantar fascia borders, plantar fascia proximal origin, the heel, and the lower leg muscle groups. The targeted soft tissues are the plantar fascia, ankle plantar flexors, heel fat pad, Achilles tendon, and the gastrocnemius-soleus complex.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrumental-assisted soft tissue mobilization (IASTM)
Description: Instrumental-assisted soft tissue mobilization (IASTM) will consist of treatment focused on the plantar surfaces of foot, posterior heel, and lower leg. The IASTM will be implemented using Graston Technique Instruments by clinicians trained and certified in the technique. Each 10-minute treatment will consist of two phases: 1) six-minute static phase, which includes tissue status screening and soft tissue mobilization, and 2) four-minute dynamic tissue mobilization phase. The treatment will focus on the web spaces of each toe plantarly, the metatarsal heads, the spaces between metatarsals, the medial and lateral plantar fascia borders, plantar fascia proximal origin, the heel, and the lower leg muscle groups. The targeted soft tissues are the plantar fascia, ankle plantar flexors, heel fat pad, Achilles tendon, and the gastrocnemius-soleus complex.
Study: NCT01544179

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gefitinib
Description: Investigational Drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo as comparator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Chemotherapy (concomitant therapy)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pemetrexed
Description: Chemotherapy (concomitant therapy)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Chemotherapy (concomitant therapy)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cisplatin
Description: Chemotherapy (concomitant therapy)
Study: NCT01251315

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo low dose
Description: This is a prospective randomized controlled pilot study, which will include twenty-four (24) healthy individuals.The first 12 subjects (low dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N Acetyl cysteine, 600mg (low dose)
Description: The sub-group of four subjects (low dose) will be given a single dose of 600 mg of N-Acetyl Cysteine (NAC).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Proimmune 200 (FT061452) 3000mg low dose
Description: The sub-group of four subjects (low dose) will be given a single dose of Proimmune 200 (FT061452) 3000mg low dose'
Study: NCT02601638

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Counseling session with speech pathologist

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Total Laryngectomy Preoperative Education Class

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day of Hospital Discharge Laryngectomy Survey

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Day of Discharge Practicum

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laryngectomy Education Study Exit Survey
Study: NCT04654221

Intervention type: DIAGNOSTIC_TEST
Intervention: mGFR by iohexol clearance
Description: Iohexol 5mL injection (300 mg iodine/mL) will be administered to all subjects to determine mGFR by iohexol clearance

Intervention type: DIAGNOSTIC_TEST
Intervention: mGFR by iohexol clearance
Description: Iohexol 5mL injection (300 mg iodine/mL) will be administered to all subjects to determine mGFR by iohexol clearance

Intervention type: DIAGNOSTIC_TEST
Intervention: mGFR by iohexol clearance
Description: Iohexol 5mL injection (300 mg iodine/mL) will be administered to all subjects to determine mGFR by iohexol clearance

Intervention type: DIAGNOSTIC_TEST
Intervention: mGFR by iohexol clearance
Description: Iohexol 5mL injection (300 mg iodine/mL) will be administered to all subjects to determine mGFR by iohexol clearance

Intervention type: DIAGNOSTIC_TEST
Intervention: mGFR by iohexol clearance
Description: Iohexol 5mL injection (300 mg iodine/mL) will be administered to all subjects to determine mGFR by iohexol clearance

Intervention type: DIAGNOSTIC_TEST
Intervention: mGFR by iohexol clearance
Description: Iohexol 5mL injection (300 mg iodine/mL) will be administered to all subjects to determine mGFR by iohexol clearance
Study: NCT04621240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online SMART & Stress Solutions
Description: 1. On-line SMART - (Strategic Memory Advanced Reasoning Training) is a curriculum that teaches strategies of how to use the brain better, in such a way that may improve brain health and performance. SMART strives to achieve optimal cognitive function realized by the brain's ability to efficiently manage complex information by abstracting its essential meaning rather than attempting to memorize details, and to prioritize the information in order to attend to the most relevant parts. 2. Stress Solutions - provides individuals with practical tools to enhance performance, reduce stress, build resilience and improve quality of life.
Study: NCT01892150

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen
Description: Apply sunscreen before and after UVA and UVB irradiation
Study: NCT03512808

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodiol 500 MG
Description: Ursodiol 500mg tablets followed by Urso Forte 500mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Urso Forte 500Mg Tablet
Description: Urso forte 500mg tablets followed by Ursodiol 500mg tablets
Study: NCT03533959

Intervention type: DRUG
Intervention: Alirocumab
Description: the administration of Alirocumab at least 75mg every 2 weeks
Study: NCT02142400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-1093
Description: DS-1093 in capsules with 2.5mg or 25mg per capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo capsules to DS-1093 capsules
Study: NCT04165382

Intervention type: OTHER
Group type: OTHER
Intervention: Interventions in the guideline to infants receiving NIV
Description: Interventions in the guideline involve six components as~1. choice of right nasal interfaces and bonnet~2. use of skin protective dressing~3. alternate the nasal interfaces every 6 hours;~4. positioning the infants at optimal developmental body position without prone every 4-6 hours, and well supporting the devices to prevent displacement and traction~5. supportive care with more new interventions~6. regular assessments on infants receiving NIV for pain level and skin integrity for the areas in contacting with the nasal interfaces and devices of NIV

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care to infants receiving NIV
Description: Usual care includes the choice of nasal interface for NIV; use of skin protective dressing; positioning of infants without specific frequency or types of position; supportive care as to provide humidification to the ventilator circuit, to remove water condensate in the ventilator circuit, to provide oral care every 3-4 hours and avoid unnecessary nasal suctioning.
Study: NCT00830375

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 10-30mg, by mouth, daily
Study: NCT00493415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nitroglycerin iv
Description: loading dose of 4mg/h iv in the first 30 minutes, 2 mg/h iv in the next 23 hours and 30 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo = nacl 0.9%
Description: 4 ml/h iv in the first 30 minutes, 2 ml /h iv in the next 23 hours and 30 minutes
Study: NCT03147755

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00752232

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001
Description: IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
Study: NCT03307629

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: NOX66 delivered as rectal suppository.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOX66
Description: NOX66 delivered as rectal suppository.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Irradiation Therapy
Description: Radiation per selected tumour lesion.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Irradiation Therapy
Description: Radiation per selected tumour lesion.
Study: NCT03155945

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorinab
Description: Olorinab active treatment for 8 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olorinab
Description: Olorinab active treatment for 8 weeks.
Study: NCT01963143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gammaplex (5%)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gammaplex (5%)
Study: NCT00752232

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QS-21
Description: IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ACC-001
Description: IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: QS-21
Description: IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
Study: NCT01963143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gammaplex 10

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gammaplex 10

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gammaplex 10
Study: NCT01251315

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (high dose)
Description: The second sub set of 12 subjects (high dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
Study: NCT00752232

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: PBS
Description: IM injection, Day 1, month 3, 6, 9, 12
Study: NCT04502589

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Perampanel Tablet
Description: Subjects will be titrated over 3 weeks to a target dose of 8mg perampanel daily in both groups
Study: NCT00315237

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinflunine and best supportive care
Description: solution for injection, IV, 280/320 mg/m2, every 3 wks variable duration
Study: NCT01844232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: arbaclofen
Description: Arbaclofen ER tablets, 20 mg, 30 mg and 40 mg
Study: NCT03850548

Intervention type: OTHER
Intervention: Prosthetic joint infection with Cutibacterium acnes
Description: patients having a prosthesis infection with C.acnes identified by specific PCR
Study: NCT00530218

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganciclovir
Description: Following the first CMV-positive blood culture on day 21 or later, or the first two consecutive CMV-positive PCR tests on day 21 or later, 5mg/kg/bid x 7 days of Ganciclovir is given intravenously, followed by oral Ganciclovir 1000 mg tid 7 days per week x 5 weeks
Study: NCT01160003

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086X
Description: 5mg and 8.75mg GW870086X once daily for 14 days in separate traetment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086X
Description: 5mg and 8.75mg GW870086X once daily for 14 days in separate traetment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GW870086X
Description: 5mg and 8.75mg GW870086X once daily for 14 days in separate traetment periods.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo will be randomly inserted into one of the treatment periods following the treatment sequences outlined in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo will be randomly inserted into one of the treatment periods following the treatment sequences outlined in the protocol.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo will be randomly inserted into one of the treatment periods following the treatment sequences outlined in the protocol.